Immunovant (IMVT)
(Delayed Data from NSDQ)
$15.71 USD
-0.37 (-2.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $15.46 -0.25 (-1.59%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMVT 15.71 -0.37(-2.30%)
Will IMVT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMVT
All You Need to Know About Immunovant (IMVT) Rating Upgrade to Buy
Wall Street Analysts See a 137.68% Upside in Immunovant (IMVT): Can the Stock Really Move This High?
IMVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock?
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
Other News for IMVT
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Immunovant (IMVT) Price Target Raised to $18 by UBS Analyst
Immunovant price target raised by $1 at UBS, here's why
UBS Raises Price Target for Immunovant (IMVT) to $18.00 | IMVT Stock News
IMVT Stock Offering Managed by Morgan Stanley Sees Wide Price Range | IMVT Stock News